The Lancet January 06, 2018

Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial

Al-Lamee et al.

Bottom Line

In a pioneering double-blind, sham-controlled trial of patients with severe single-vessel coronary artery disease and stable angina, percutaneous coronary intervention did not significantly increase exercise time compared with a placebo procedure.

Key Findings

1. Among 200 randomized patients with severe coronary stenosis (mean area stenosis 84.4%, mean fractional flow reserve 0.69), there was no significant difference in the primary endpoint of exercise time increment between the PCI and placebo groups (difference of PCI minus placebo: 16.6 s, 95% CI -8.9 to 42.0, p=0.200).

2. No deaths occurred in either study group during the trial.

3. Serious adverse events were rare but included four pressure-wire related complications in the placebo group that required subsequent PCI.

4. Five major bleeding events were observed during the trial (2 in the PCI group and 3 in the placebo group).

Study Design

Design

RCT

Double-Blind

Sample

200

Patients

Duration

6 wk

Median

Setting

Multicenter, UK

Population Patients with medically treated angina and severe (≥70%) single-vessel coronary stenoses

Intervention Percutaneous coronary intervention (PCI)

Comparator Placebo (sham) procedure

Outcome Difference in exercise time increment between groups

Study Limitations

• The 6-week follow-up period after randomization was very short, limiting the ability to assess long-term symptomatic relief or downstream clinical divergence.

• The intensive 6-week pre-randomization medical optimization phase (often resulting in patients taking multiple antianginal medications) does not reflect typical real-world clinical practice and may have minimized the potential symptomatic benefit of PCI.

• The study enrolled a relatively small sample size (N=200 randomized) restricted exclusively to patients with single-vessel disease, meaning results may not generalize to patients with multi-vessel disease or highly refractory symptoms.

Clinical Significance

ORBITA profoundly challenged the widely held clinical belief that PCI provides reliable symptomatic relief for stable angina beyond a placebo effect. By establishing the feasibility and ethical acceptability of sham-controlled interventional cardiology trials, ORBITA underscored the paramount importance of maximizing optimal medical therapy as the foundation of care for stable ischemic heart disease, fundamentally altering how interventional benefits are perceived.

Historical Context

Prior to ORBITA, landmark trials such as COURAGE and BARI 2D had convincingly demonstrated that PCI does not reduce mortality or the risk of myocardial infarction in patients with stable coronary disease when compared to optimal medical therapy. Nonetheless, PCI remained the standard of care for symptom relief because unblinded data suggested it improved angina better than medications alone. Because no previous trials had utilized a sham control, the magnitude of the placebo effect inherent to an invasive cardiac procedure was entirely unknown. ORBITA was the first trial to rigorously isolate the physical efficacy of PCI from its powerful placebo effect in stable angina, prompting an intense global debate and re-evaluation of revascularization guidelines.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

How does the pathophysiology of stable angina explain why relieving a focal epicardial stenosis with PCI might not necessarily eliminate exertional symptoms, and what role does the placebo effect play in this subjective relief?

Key Response

Stable angina is driven by a mismatch between myocardial oxygen supply and demand. While PCI restores epicardial patency (supply), it does not address microvascular dysfunction, endothelial function, or myocardial oxygen demand. The ORBITA trial highlights that a significant portion of symptom relief post-PCI is attributable to the placebo effect, as subjective symptoms like chest pain are highly susceptible to patient expectations following an invasive procedure.

Resident

A 60-year-old patient with stable exertional angina and an 80% LAD lesion is eager to get a stent to 'cure' their chest pain. Based on the ORBITA trial, how should you counsel this patient regarding the initial approach of PCI versus optimal medical therapy (OMT)?

Key Response

The resident must apply ORBITA to shared decision-making. The trial demonstrated that in patients with severe single-vessel disease, PCI did not significantly improve exercise time over a sham procedure when patients were already on intensive OMT. Counseling should emphasize that OMT (antianginals, statins, aspirin) is the foundational therapy, and PCI should be reserved for refractory symptoms rather than used as an initial 'cure' for stable angina.

Fellow

ORBITA included patients with severe single-vessel disease, many with hemodynamically significant lesions by FFR or iFR. How do concepts like coronary microvascular dysfunction (CMD) and diffuse atherosclerosis help explain the lack of functional improvement in patients despite anatomically and physiologically successful epicardial revascularization?

Key Response

Fellows should understand that FFR/iFR primarily assess focal epicardial resistance. However, coronary flow reserve is heavily dependent on the microcirculation. If a patient has concurrent CMD or diffuse distal disease (common in atherosclerosis), relieving a single epicardial bottleneck will not fully restore hyperemic flow or relieve ischemia. ORBITA forces a paradigm shift from a purely focal anatomical approach to considering the entire coronary tree and microvasculature.

Attending

Historically, the 'oculostenotic reflex' drove the treatment of stable CAD. How does ORBITA fundamentally challenge our threshold for offering PCI in stable angina, and how can we effectively teach trainees to decouple anatomical severity from the automatic decision to revascularize?

Key Response

ORBITA serves as a profound teaching tool for Attendings to combat the oculostenotic reflex—the urge to stent a severe lesion simply because it is there. The rationale highlights the necessity of treating the patient's symptoms rather than the angiogram. It reinforces teaching trainees to optimize medical therapy rigorously before considering PCI, and to manage patient expectations about the genuine functional benefits of stenting in the absence of acute coronary syndromes.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

ORBITA was groundbreaking for its use of a sham-control in invasive cardiology. What are the methodological trade-offs of the trial's short 6-week follow-up period, and how does this affect the study's statistical power and the generalizability of its primary endpoint (exercise time)?

Key Response

A 6-week follow-up was chosen to maintain clinical safety and ethical feasibility for the sham arm, ensuring they were not deprived of potential true revascularization for too long. However, this methodological compromise risks missing late benefits of PCI (e.g., after vascular healing) or late failures of medical therapy. Furthermore, exercise time is a surrogate marker with high variance, meaning the short timeframe and small sample size might have left the study underpowered to detect smaller, yet clinically meaningful, differences.

Journal Editor

As a peer reviewer evaluating ORBITA, how would you critique the impact of the intense 6-week medical optimization phase prior to randomization? Does this pre-optimization create an artificially high baseline that threatens the external validity (generalizability) of the null findings to real-world populations?

Key Response

A critical reviewer would note that the 6-week run-in phase involved intensive medication titration (up to 3 antianginals) via frequent physician phone calls, which rarely happens in routine clinical practice. This aggressive optimization likely maximized the baseline exercise capacity of both groups, shrinking the potential delta (effect size) that PCI could add. This threatens external validity, as real-world patients are often less adherent or sub-optimally medically managed, where PCI might actually show a larger relative benefit.

Guideline Committee

Given that previous ACC/AHA guidelines provided a strong recommendation for PCI to improve symptoms in stable ischemic heart disease, how should the ORBITA trial findings influence the phrasing, strength of recommendation, and level of evidence for PCI in future guideline iterations?

Key Response

Guideline committees must reconcile ORBITA's sham-controlled data with older, unblinded trials (like COURAGE) that suggested some symptomatic benefit. ORBITA downgraded the certainty that PCI provides superior angina relief compared to aggressive medical therapy alone. Consequently, guidelines should emphasize a Class I recommendation for intensive OMT first, downgrading PCI to a step-up therapy strictly for patients whose angina remains unacceptable despite maximized OMT, with the Level of Evidence for PCI's symptomatic benefit reflecting the placebo effect highlighted by ORBITA.

Clinical Landscape

Noteworthy Related Trials

2007

COURAGE Trial

n = 2,287 · NEJM

Tested

PCI plus Optimal Medical Therapy (OMT)

Population

Patients with stable coronary artery disease

Comparator

OMT alone

Endpoint

Death from any cause and nonfatal myocardial infarction

Key result: PCI did not reduce the risk of death, myocardial infarction, or other major cardiovascular events when added to optimal medical therapy.

2012

FAME 2 Trial

n = 1,220 · NEJM

Tested

Fractional flow reserve (FFR)-guided PCI plus OMT

Population

Patients with stable coronary artery disease and functionally significant stenosis

Comparator

OMT alone

Endpoint

Composite of death, myocardial infarction, or urgent revascularization

Key result: FFR-guided PCI plus optimal medical therapy decreased the rate of the primary composite endpoint, driven primarily by a lower rate of urgent revascularization.

2020

ISCHEMIA Trial

n = 5,179 · NEJM

Tested

Routine invasive strategy (angiography and revascularization) plus OMT

Population

Patients with stable coronary disease and moderate to severe ischemia

Comparator

Conservative strategy (OMT alone)

Endpoint

Composite of cardiovascular death, myocardial infarction, or hospitalization for unstable angina, heart failure, or resuscitated cardiac arrest

Key result: An initial invasive strategy did not demonstrate a reduced risk of ischemic cardiovascular events or death from any cause over a conservative strategy.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis